Sorbitol
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Sorbitol: From Unrecorded Original Indication to Exercise-Induced Malignant Hyperthermia
One-Sentence Summary
Sorbitol’s original approved indication and mechanism of action are not currently documented in this evidence pack (data gap). The TxGNN model predicts a possible association with Exercise-Induced Malignant Hyperthermia, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-only signal with no mechanistic or clinical corroboration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication text on record |
| Predicted New Indication | Exercise-Induced Malignant Hyperthermia |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for sorbitol (recorded as a data gap). No original indication is on file either, so the drug’s established therapeutic context cannot be compared against the predicted indication.
Based on the rationale provided with this prediction, sorbitol is generally known as an osmotic agent/sugar alcohol. Exercise-induced malignant hyperthermia is pathophysiologically driven by RYR1/CACNA1S mutations causing abnormal calcium release from the skeletal muscle sarcoplasmic reticulum, typically triggered by volatile anesthetics or succinylcholine. There is no known pharmacological pathway connecting sorbitol to calcium channel regulation or malignant hyperthermia pathophysiology.
This prediction should be treated as a statistical association from the TxGNN knowledge graph (score 0.994) rather than a mechanistically grounded hypothesis. The evidence pack itself flags this link as lacking mechanistic plausibility, and no clinical or literature evidence currently exists to support it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Sorbitol has no recorded market authorizations in this evidence pack (0 licenses; status: Not Marketed). No product/dosage-form/indication data is available to tabulate.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications are marked as a Blocking data gap — this must be resolved before any safety-relevant decision can be made.)
Conclusion and Next Steps
Decision: Hold
Rationale: There is no mechanistic, clinical, or literature evidence supporting this prediction — it rests solely on a TxGNN knowledge-graph score (L5). Combined with missing MOA data and a Blocking gap in TFDA safety labeling, this candidate does not meet the minimum bar to advance to safety screening (S1).
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001, Blocking) — required before any S1 safety evaluation
- Confirmed mechanism of action (DG002, High) — required to assess mechanistic plausibility
- Original approved indication(s) for sorbitol, to establish a baseline for comparison
- Any preclinical or case-level evidence specifically linking sorbitol to malignant hyperthermia pathways, if it exists
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.